Prescribing information

 

How MAYZENT works in SPMS with active disease.

MAYZENT is a novel therapy for SPMS with active disease1

Selective S1P1 and S1P5 receptor modulator1

  • Potent effect on S1P1 and S1P5 receptors, which are widely expressed on cells of the immune system and the CNS.

Impacts MS pathology1–4

  • Inhibits the egress of lymphocytes from lymph nodes to reduce CNS inflammation.

Distribution and elimination1

  • Readily crosses the blood-brain barrier.
  • Short half-life of ~30 hours with a washout period of around 10 days.

 Image of the chemical structure of siponimod

 

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.5

CNS, central nervous system; MS, multiple sclerosis; S1P, sphingosine-1-phosphate; SPMS, secondary progressive multiple sclerosis.

References

  1. Novartis DOF_GLNS_SIPO_0127.
  2. Kappos L et al. Lancet. 2018;391:1263–1273, plus supplementary appendix.
  3. Benedict RHB et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: results from the phase 3 EXPAND study. Poster presented at: AAN Meeting; 26 April 2018; Los Angeles, CA, USA.
  4. Arnold DL et al. Presented at: the 35th ECTRIMS Congress; 11–13 September 2019; Stockholm, Sweden.
  5. MAYZENT (siponimod) Summary of Product Characteristics.
SIP20-C001c May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]